The Kidney PATIENT Act of 2023 (H.R. 5074) prevents the Centers for Medicare and Medicaid Services (CMS) from adding phosphate binders/lowering drugs to the Medicare ESRD PPS until January 2033, unless an intravenous drug is approved by the Food and Drug Administration to control or manage serum phosphate levels. This important legislation would preserve access to oral-only phosphate binders/lowering drugs for individuals living with CKD and reduce the burden on small and independent dialysis facilities.